By Amy Johnson – For pharmaceutical manufacturers and life sciences organizations, ensuring patients use medications as intended is central to outcomes, safety, and adherence. But when EHR prescribing workflows introduce ambiguity, especially with patient instructions, those goals become harder to achieve.
Read More
We have rounded up some reports and surveys from around the industry that we thought were of interest from Luna Physical Therapy, Royal Philips, Cognizant, Nordic Consulting Partners, Wolters Kluwer Health, Incredible Health, Physicians for Human Rights, HealthEdge, MedPAC, Accenture, HHAeXchange, and more.
By Devin Partida – As the health IT industry has gained momentum, it has strengthened the pharmaceutical supply chain, providing many benefits to patients, medication producers and health care providers. What specific advantages can strategically applied technologies bring to supply chain management?
By Amber Glende – If you work in life sciences, whether in pharma, diagnostics, or vaccines, Federally Qualified Health Centers might not be on your radar. Many manufacturers focus their commercial strategies on large health systems, private practices, and specialty networks, leaving FQHCs largely untapped.
NOW on Demand This Just In episode with host Justin Barnes and his guests Harini Malik, Worldwide Strategic Business Development Lead: Public Sector, Telco, Healthcare, and Retail from AMD, and Sandra Colner, General Manager for Healthcare and Life Science Alliances at Dell Technologies
Our annual predictions for 2025 continue with AI in Life Sciences. Throughout the next few weeks we will be asking the industry experts what they think we will see in 2025. Check back as we cover value-based care, interoperability, virtual care, and how AI will impact healthcare finance, security, RCM, and clinical issues.
By Kim Boyd – In an era where data fluidity is transforming healthcare, life sciences manufacturers must stay attuned to evolving Health IT policies given that many of these policies have downstream effects on life sciences and access to expanded deidentified and aggregated datasets.
NOW on-demand, Value-Based Care Insights host Daniel J. Marino speaks with Hal Katz, a partner at Husch Blackwell specializing in healthcare life sciences. Gain insights into the FTC ruling on physician employment agreements, the required alignment between single-specialty groups health systems, and more.
By Tom Dorsett – As of April 2023, the FDA has approved the use of 40 “biosimilars”, which are a less expensive version of an advanced “biologic” medication. The rise of biosimilars is a major source of excitement as a way to control rising drug costs. But is the fervor warranted?